Thus, TGF-β1 is considered as a potential biomarker for renal fibrosis and inhibiting TGF-β1/Smad2/3 pathway may represent an effective therapy for DN associated with progressive real fibrosis [9]. This evidence concerns the gene TGFB1 and renal fibrosis.